Loading…
Japanese manufacturer of generic (off-patent) pharmaceutical drugs sold to hospitals and pharmacies.
Japanese manufacturer of generic (off-patent) pharmaceutical drugs sold to hospitals and pharmacies.
Prices for its drugs are set on the government's reimbursement list and cut regularly, so it competes on volume gained when doctors and pharmacies switch patients to generics and on production cost, since the selling price is not negotiable. It also makes drugs on contract for other pharma companies.
In one line: Japan's Teva / Viatris.
Moat: none (scale, regulatory licence). Generic drug maker competing on cost and government-mandated price cuts, with little product differentiation.
Headquarters: Osaka, Japan · Founded: 1951 · Employees: 4,923
Size Towa Pharmaceutical (4553.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $1.03B, the 721st largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥3,310 on 6 Nov 2026.
Performance Over six months the shares fell 16.4%, against -13.0% for the median peer and +1.8% for the Japan market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 6.8% over the last twelve months (peer median +8.0%); the operating margin is 8.7% (peer median 6.6%).
Valuation It trades at 7.0× forward earnings against a peer median of 21.0× (2nd cheapest of 12).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -11 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.4 points below its cost of capital (5.0% WACC).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥280B | ¥274B | ¥260B | ¥228B | ¥209B |
| Revenue growth | — | +5% | +14% | +9% | — |
| Gross profit | ¥102B | ¥99.1B | ¥94.7B | ¥81.4B | ¥72.7B |
| EBITDA | ¥47.1B | ¥45.9B | ¥43.3B | ¥35.5B | ¥24.9B |
| Net income | ¥8.27B | ¥5.25B | ¥19.0B | ¥16.2B | ¥2.20B |
| Free cash flow | ¥4.28B | ¥8.15B | -¥5.33B | -¥29.6B | -¥26.2B |
| Capital expenditure | ¥22.9B | ¥24.1B | ¥31.2B | ¥39.3B | ¥30.5B |
| Total debt | ¥230B | ¥227B | ¥231B | ¥202B | ¥162B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Towa Pharmaceutical 4553.T | $1.03B | -16% | +7% | 9% | 7.0× | 1.5% |
| SAWAI 4887.T | $1.03B | -22% | +11% | 9% | 10.9× | n/a |
| Viatris VTRS | $22.9B | +17% | +5% | 10% | 7.5× | 12.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4553.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.6% | -2.3% | 6th lowest of 21 |
| 6-month return | -16.4% | -13.0% | 8th lowest of 20 |
| Distance from 52-week high | -26.3% | -32.2% | 9th highest of 21 |
| Revenue growth (TTM) | +6.8% | +8.0% | 9th lowest of 18 |
| Operating margin | 8.7% | 6.6% | 8th highest of 18 |
| Forward P/E | 7.0× | 21.0× | 2nd cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | 1.5% | 4.2% | 5th least demanding of 13 |
| Growth delivered (Del g) | +12.1% | +0.7% | 5th highest of 13 |
| Hurdle (Req g minus delivered) | -10.5 pp | +2.1 pp | 3rd least demanding of 13 |
| ROIC minus cost of capital | -0.4 pp | -1.7 pp | 7th highest of 16 |
| EV / EBITDA | 7.4× | 13.2× | cheapest of 8 |
| Net debt / EBITDA | 4.0× | 0.4× | 2nd most indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 7.0× | 1.5% | +12.1% |
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 10.9× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $1.03B | -11% | -43% | -42% | n/a | 11.9% | -13.7% |
| Oscotec 039200.KS | South Korea | $1.02B | -30% | +233% | 62% | 56.8× | -9.5% | +18.1% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -13% | +31% | -7% | 4.8× | -6.4% | -7.7% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 21.0× | 3.4% | +1.8% |
| Harrow HROW | United States | $1.01B | -30% | +21% | 2% | 21.9× | 51.8% | +41.0% |
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 17.7× | -9.4% | -7.0% |
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 23.8× | n/a | n/a |
| KPC Pharmaceuticals 600422.SS | China | $1.00B | -7% | -41% | -10% | n/a | n/a | n/a |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | n/a | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $999M | -15% | -16% | 13% | n/a | 8.8% | -6.9% |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 12.4× | -5.7% | +12.7% |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 30.3× | 38.6% | +20.4% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | n/a | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | n/a | 34.1% | -6.0% |
| Savara SVRA | United States | $992M | -8% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% | +3.5% |
| SSY 2005.HK | Hong Kong | $990M | +10% | -4% | 12% | 13.0× | 2.1% | -0.5% |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |